Image Place holder

Pamela Joy Hodul, MD


Specialty: Surgery
Program: Gastrointestinal Oncology

Call 1-888-MOFFITT
(1-888-663-3488)

or call 1-888-MOFFITT
(1-888-663-3488)

Overview

Dr. Pamela Hodul is a surgical oncologist and medical director of the Nutrition Support Team in the Department of Gastrointestinal Oncology at Moffitt Cancer Center.  She is an assistant professor of oncology at the University of South Florida College of Medicine. Dr. Hodul’s clinical interest includes gastrointestinal malignancies with particular interest in pancreas, liver, biliary, gastric, islet cell and carcinoid tumors.  Her research focuses on identifying novel molecular targets involved in the development and progression of pancreatic and neuroendocrine tumors. Dr. Hodul graduated magna cum laude from Loyola University Chicago Stritch School of Medicine in Chicago, IL.  She completed her surgical residency training at Loyola, where she was named chief administrative surgical resident her last year.   Dr. Hodul then came to Moffitt for a clinical fellowship in surgical oncology, followed by a research fellowship in the Department of Gastrointestinal Oncology. Dr. Hodul has received numerous awards, including the Angel Award presented by Moffitt patients or patients’ families (2006, 2007, 2008 and 2009). She also received the Most Compassionate Doctor Award in 2011 by MDx Medical, as well as MDx Medical’s Patients’ Choice Award in 2010 and 2011. Dr. Hodul is widely published and is a member of many professional organizations, including the Society of Surgical Oncology and North American Neuro Endocrine Tumor Society.

Education & Training

Board Certification:

  • Surgery

Fellowship:

  • H. Lee Moffitt Cancer Center & Research Institute - Surgical Oncology
  • H. Lee Moffitt Cancer Center & Research Institute - Surgical Oncology

Residency:

  • Loyola University Chicago Stritch School of Medicine - Surgery

Medical School:

  • Loyola University Chicago Stritch School of Medicine - MD
Participating Trials

CLINICAL TRIAL 14882
Protocol for High-Risk Assessment, Screening, and Early Detection of Pancreatic Cancer at Moffitt Cancer Center
Condition: Gastrointestinal Tumor
Intervention:
Open

If you believe you are eligible for one of these trials or studies, please call
1-888-MOFFITT (1-888-663-3488).

Publications

  • Mellon EA, Jin WH, Frakes JM, Centeno BA, Strom TJ, Springett GM, Malafa MP, Shridhar R, Hodul PJ, Hoffe SE. Predictors and survival for pathologic tumor response grade in borderline resectable and locally advanced pancreatic cancer treated with induction chemotherapy and neoadjuvant stereotactic body radiotherapy. Acta Oncol. 2017 Mar;56(3):391-397. Pubmedid: 27885876.
  • Blackham AU, Doepker MP, Centeno BA, Springett G, Pimiento JM, Malafa M, Hodul PJ. Patterns of recurrence and long-term outcomes in patients who underwent pancreatectomy for intraductal papillary mucinous neoplasms with high grade dysplasia: implications for surveillance and future management guidelines. HPB (Oxford). 2017 Jul;19(7):603-610. Pubmedid: 28495434.
  • Glazer ES, Rashid OM, Klapman JB, Harris CL, Hodul PJ, Pimiento JM, Malafa MP. Endoscopic ultrasonography complements computed tomography in predicting portal or superior mesenteric vein resection in patients with borderline resectable pancreatic carcinoma. Pancreatology. 2017 Aug;17(1):130-134. Pubmedid: 28043760.
  • Pearson AL, Jin W, Mellon EA, Frakes JM, Strom T, Springett GM, Kim R, Mahipal A, Hodul PJ, Pimiento JM, Shridhar R, Malafa MP, Hoffe SE. Post-Stereotactic Body Radiation Therapy (SBRT) Neutrophil-to-Lymphocyte Ratio (NLR) in Patients With Borderline Resectable Pancreatic Cancer (BRPC) May Be a Prognostic Biomarker. Int J Radiat Oncol Biol Phys. 2016 Oct;96(2S):E153. Pubmedid: 27673917.
  • Glazer ES, Neill KG, Frakes JM, Coppola D, Hodul PJ, Hoffe SE, Pimiento JM, Springett GM, Malafa MP. Systematic Review and Case Series Report of Acinar Cell Carcinoma of the Pancreas. Cancer Control. 2016 Oct;23(4):446-454. Pubmedid: 27842335.
  • Mellon EA, Hoffe SE, Frakes JM, Strom T, Springett GM, Shridhar R, Centeno BA, Malafa MP, Chuong MD, Hodul PJ. Predictors and Survival for Pathologic Tumor Response Grade in Borderline Resectable and Locally Advanced Pancreatic Cancer Treated With Induction Chemotherapy and Neoadjuvant Stereotactic Body Radiation Therapy. Int J Radiat Oncol Biol Phys. 2016 Oct;96(2S):E165. Pubmedid: 27673949.
  • Hall M, Liu H, Malafa M, Centeno B, Hodul PJ, Pimiento J, Pilon-Thomas S, Sarnaik AA. Expansion of tumor-infiltrating lymphocytes (TIL) from human pancreatic tumors. J Immunother Cancer. 2016 Oct;4:61. Pubmedid: 27777771. Pmcid: PMC5067894.
  • Glazer ES, Rashid OM, Pimiento JM, Hodul PJ, Malafa MP. Increased neutrophil-to-lymphocyte ratio after neoadjuvant therapy is associated with worse survival after resection of borderline resectable pancreatic ductal adenocarcinoma. Surgery. 2016 Nov;160(5):1288-1293. Pubmedid: 27450715. Pmcid: PMC5086285.
  • Robinson LA, Tanvetyanon T, Springett G, Fontaine J, Toloza E, Hodul P, Pimiento JM, Malafa M. Pulmonary metastasectomy for suspected pancreaticobiliary cancer. J Thorac Cardiovasc Surg. 2016 Jul;152(1):75-82. Pubmedid: 27050555.
  • Doepker MP, Thompson ZJ, Centeno BA, Kim RD, Wong J, Hodul PJ. Clinicopathologic and survival analysis of resected ampullary adenocarcinoma. J Surg Oncol. 2016 Aug;114(2):170-175. Pubmedid: 27158031.
  • Rashid OM, Pimiento JM, Gamenthaler AW, Nguyen P, Ha TT, Hutchinson T, Springett G, Hoffe S, Shridhar R, Hodul PJ, Johnson BL, Illig K, Armstrong PA, Centeno BA, Fulp WJ, Chen DT, Malafa MP. Outcomes of a Clinical Pathway for Borderline Resectable Pancreatic Cancer. Ann Surg Oncol. 2016 Apr;23(4):1371-1379. Pubmedid: 26661409.
  • Strom TJ, Klapman JB, Springett GM, Meredith KL, Hoffe SE, Choi J, Hodul P, Malafa MP, Shridhar R. Comparative long-term outcomes of upfront resected pancreatic cancer after preoperative biliary drainage. Surg Endosc. 2015 Nov;29(11):3273-3281. Pubmedid: 25631110. Pmcid: PMC4918460.
  • Kim R, Prithviraj G, Kothari N, Springett G, Malafa M, Hodul P, Kim J, Yue B, Morse B, Mahipal A. PET/CT Fusion Scan Prevents Futile Laparotomy in Early Stage Pancreatic Cancer. Clin Nucl Med. 2015 Nov;40(11):e501-e505. Pubmedid: 26053713. Pmcid: PMC4813735.
  • Frakes JM, Strom T, Springett GM, Hoffe SE, Balducci L, Hodul P, Malafa MP, Shridhar R. Resected pancreatic cancer outcomes in the elderly. Geriatr Oncol. 2015 Mar;6(2):127-132. Pubmedid: 25555451.
  • Mellon EA, Hoffe SE, Springett GM, Frakes JM, Strom TJ, Hodul PJ, Malafa MP, Chuong MD, Shridhar R. Long-term outcomes of induction chemotherapy and neoadjuvant stereotactic body radiotherapy for borderline resectable and locally advanced pancreatic adenocarcinoma. Acta Oncol. 2015 Jul;54(7):979-985. Pubmedid: 25734581.
  • Jones DH, Caracciolo JT, Hodul PJ, Strosberg JR, Coppola D, Bui MM. Familial gastrointestinal stromal tumor syndrome: report of 2 cases with KIT exon 11 mutation. Cancer Control. 2015 Jan;22(1):102-108. Pubmedid: 25504284.
  • Wong J, Fulp WJ, Strosberg JR, Kvols LK, Centeno BA, Hodul PJ. Predictors of lymph node metastases and impact on survival in resected pancreatic neuroendocrine tumors: a single-center experience. Am J Surg. 2014 Nov;208(5):775-780. Pubmedid: 24997491.
  • Toloza E, Sobky C, Cheng A, Chai C, Smithson I, Brown L, Moodie C, Garrett J, Parsons C, Hodul P, Malafa M. Robotic-assisted video-thoracoscopic closure of pancreatico-pleural fistula: a case report. Chest. 2014 Mar;145(3 Suppl):36A. Pubmedid: 24638364.
  • Mellon EA, Springett GM, Hoffe SE, Hodul P, Malafa MP, Meredith KL, Fulp WJ, Zhao X, Shridhar R. Adjuvant radiotherapy and lymph node dissection in pancreatic cancer treated with surgery and chemotherapy. Cancer. 2014 Apr;120(8):1171-1177. Pubmedid: 24390779.
  • Chuong MD, Springett GM, Freilich JM, Park CK, Weber JM, Mellon EA, Hodul PJ, Malafa MP, Meredith KL, Hoffe SE, Shridhar R. Stereotactic body radiation therapy for locally advanced and borderline resectable pancreatic cancer is effective and well tolerated. Int J Radiat Oncol Biol Phys. 2013 Jul;86(3):516-522. Pubmedid: 23562768.
  • Wong J, Weber J, A Centeno B, Vignesh S, Harris CL, Klapman JB, Hodul P. High-grade dysplasia and adenocarcinoma are frequent in side-branch intraductal papillary mucinous neoplasm measuring less than 3 cm on endoscopic ultrasound. J Gastrointest Surg. 2013 Jan;17(1):78-84. Pubmedid: 22948841.
  • Hodul PJ, Dong Y, Husain K, Pimiento JM, Chen J, Zhang A, Francois R, Pledger WJ, Coppola D, Sebti SM, Chen DT, Malafa MP. Vitamin E δ-tocotrienol induces p27(Kip1)-dependent cell-cycle arrest in pancreatic cancer cells via an E2F-1-dependent mechanism. PLoS One. 2013 Aug;8(2):e52526. Pubmedid: 23393547. Pmcid: PMC3564846.
  • Strosberg JR, Cheema A, Weber JM, Ghayouri M, Han G, Hodul PJ, Kvols LK. Relapse-free survival in patients with nonmetastatic, surgically resected pancreatic neuroendocrine tumors: an analysis of the AJCC and ENETS staging classifications. Ann Surg. 2012 Aug;256(2):321-325. Pubmedid: 22415420.
  • Nasir A, Helm J, Turner L, Chen DT, Strosberg J, Hafez N, Henderson-Jackson EB, Hodul P, Bui MM, Nasir NA, Hakam A, Malafa MP, Yeatman TJ, Coppola D, Kvols LK. RUNX1T1: a novel predictor of liver metastasis in primary pancreatic endocrine neoplasms. Pancreas. 2011 May;40(4):627-633. Pubmedid: 21499216. Pmcid: PMC4732279.
  • Chuong MD, Hayman TJ, Patel MR, Russell MS, Malafa MP, Hodul PJ, Springett GM, Choi J, Shridhar R, Hoffe SE. Comparison of 1-, 2-, and 3-Dimensional Tumor Response Assessment After Neoadjuvant GTX-RT in Borderline-Resectable Pancreatic Cancer. Gastrointest Cancer Res. 2011 Jul;4(4):128-134. Pubmedid: 22368736. Pmcid: PMC3283109.
  • Patel M, Hoffe S, Malafa M, Hodul P, Klapman J, Centeno B, Kim J, Helm J, Valone T, Springett G. Neoadjuvant GTX chemotherapy and IMRT-based chemoradiation for borderline resectable pancreatic cancer. J Surg Oncol. 2011 Aug;104(2):155-161. Pubmedid: 21520097. Pmcid: PMC3347705.
  • Helm J, Centeno B, Coppola D, Druta M, Park J, Chen D, Hodul P, Kvols LK, Yeatman T, Carey L, Karl R, Malafa M. Outcomes following resection of pancreatic adenocarcinoma: 20-year experience at a single institution. Cancer Control. 2008 Oct;15(4):288-294. Pubmedid: 18813196.
  • Hodul P, Strosberg J, Kvols L. Aggressive surgical resection in the management of pancreatic neuroendocrine tumors: when is it indicated. Cancer Control. 2008 Oct;15(4):314-321. Pubmedid: 18813199.
  • Park J, Helm J, Zheng W, Ly Q, Hodul P, Centeno B, Malafa M. Silencing of the candidate tumor suppressor gene solute carrier family 5 member 8 (SLC5A8) in human pancreatic cancer. Pancreas. 2008 May;36(4):e32-e39. Pubmedid: 18437076.
  • Strosberg JR, Nasir A, Hodul P, Kvols L. Biology and treatment of metastatic gastrointestinal neuroendocrine tumors. Gastrointest Cancer Res. 2008 May;2(3):113-125. Pubmedid: 19259290. Pmcid: PMC2633071.
  • Hodul P, Malafa M, Choi J, Kvols L. The role of cytoreductive hepatic surgery as an adjunct to the management of metastatic neuroendocrine carcinomas. Cancer Control. 2006 Jan;13(1):61-71. Pubmedid: 16508628.
  • Hodul P, Yeatman T. TNM staging is obsolete. J Surg Oncol. 2006 Dec;95(1):8-9. Pubmedid: 17192885.